

Press Release

Eurofins Genomics meets global demand for SARS-CoV-2 full genome sequencing, with over 100,000 sequenced samples in less than 8 weeks

Ebersberg, Germany, 18.05.2021:

Eurofins Genomics Europe, a leader in genomic products and services, is further expanding its SARS-CoV-2 full genome sequencing capacity. The laboratory in Constance, Germany, has sequenced more than 100,000 SARS-CoV-2 samples from 23 countries in the past three months. Eurofins Genomics Europe's "ARTIC SARS-CoV-2 Whole Genome Sequencing" service includes next-generation sequencing (NGS) and detailed reporting for universal end-to-end surveillance of pandemic development, tracking the emergence and dynamics of existing and new mutational Variants of Concern.

The service was launched in December 2020 and was designed to facilitate global genomic scientific insights into SARS-CoV-2, providing scientists with the right tools to identify fast and viable measures against the pandemic. With an increasing focus on Variants of Concern, the service was used by many countries and European organisations to support national responses to observed mutant variants. With a turnaround time of as little as 5 days and a capacity of 35,000 viral genomes per week, Eurofins Genomics Europe continues to contribute to the fight against the pandemic. Future investments will lead to a further increase in capacity in the coming weeks.

The "SARS-CoV-2 Full-length Genome Sequencing" service provides Eurofins Genomics' customers with a fully assembled sequence of the viral ssRNA genome. It enables accurate lineage and variant identification, surveillance of emerging and spreading Variants of Concern, as well as phylogenetic analyses between locally and regionally different viral isolates. A sophisticated bioinformatics analyses and reporting pipeline provides comprehensive SNP and variant reporting, including lineage classification, facilitating conclusive interpretation of data.

Eurofins Genomics Europe's "SARS-CoV-2 Full-length Genome Sequencing" service is an important part of the Eurofins Group's commitment to contributing to the global response to the SARS-CoV-2 crisis. Eurofins Genomics Europe supports scientists from across the world in their vital work by providing them with the right tools to facilitate genomic research on SARS-CoV-2. The COVID-19 product range covers the entire spectrum of genomic possibilities: SARS-CoV-2 qPCR tests, assays, plasmid controls, RT-PCR kits, wastewater and surface tests. Further information on Eurofins Genomics Germany's entire COVID-19 testing portfolio can be found on <https://www.eurofinsgenomics.eu/en/covid-19/>.

More information on the "SARS-CoV-2 Full-length Genome Sequencing" service can be found on <https://eurofinsgenomics.eu/en/next-generation-sequencing/applications/artic-sars-cov-2-rna-seq/>

For Further Information:

Media Contact: Julian Schlossmacher
Head of Marketing and Communications Eurofins Genomics Europe
+49 8092 8289 925
julianschlossmacher@eurofins.com

Eurofins Genomics Website: www.eurofinsgenomics.com

Notes to Editors:

About Eurofins Genomics – a global leader in genomic products and services Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its extensive customer base and high-quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit www.eurofinsgenomics.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agrosience CRO services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialized and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 50,000 staff across a decentralized and entrepreneurial network of more than 800 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.

In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has

carried out over 18 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programs to help ensure safer environments during COVID-19.

Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).